|Articles|December 10, 2001

CDER News 12/5 and 12/6 2001

Author(s)BioPharm International Editors

New and generic drug approvals

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content

FAQ: What Precision Analytics Have Done to Advance Next-Gen Biologics

ByFeliza Mirasol

December 19th 2025

Ask the Expert: Training for a Skilled Workforce

BySusan J. Schniepp,Siegfried Schmitt,Susan Haigney

December 18th 2025

FAQ: What You Need to Know about the Current Antibody Pipeline

ByFeliza Mirasol

December 18th 2025

Global shipping and supply chain vector illustration. Abstract concept with world map background and connected icons related to international import / export, distribution and transportation. | Image credit: © j-mel - © j-mel - stock.adobe.com

Norgine Secures Hepatitis Delta Therapy Rights Across Key Region

ByFeliza Mirasol

December 17th 2025

Behind the Headlines Episode 30: 2026 Wish List

ByChris Spivey

December 17th 2025

CDER News 12/5 and 12/6 2001

Newsletter

Related Content

FAQ: What Precision Analytics Have Done to Advance Next-Gen Biologics

Ask the Expert: Training for a Skilled Workforce

FAQ: What You Need to Know about the Current Antibody Pipeline

Norgine Secures Hepatitis Delta Therapy Rights Across Key Region

Behind the Headlines Episode 30: 2026 Wish List

Trending on BioPharm International

Developing Next-Gen Cell Lines Using Targeted Integration

FAQ: What You Need to Know about the Current Antibody Pipeline

FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model

Inside Codexis: Redefining Pharma Biocatalysis

EU Clears Subcutaneous Biologic for Lupus, Advancing Patient-Controlled Delivery